Semax
Research OnlyA synthetic heptapeptide analogue of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension, developed by Russian researchers and approved in Russia since ~1997 for stroke, cognitive impairment, and optic nerve disorders. Demonstrates nootropic and neuroprotective effects through BDNF/NGF upregulation, dopaminergic and serotonergic modulation, and anti-inflammatory mechanisms. Extensive Russian clinical research supports efficacy, particularly in stroke rehabilitation, though Western independent replication remains limited.
ACTH(4-7)PGP · Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline · MEHFPGP
8 human studies
- Preclinical
- 75%
- Clinical
- 25%
Based on 32 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 58: best human tier is multiple controlled clinical trials — Gusev 2018 (29798983, n=110 post-stroke, BDNF + Barthel) plus a placebo-controlled fMRI study (32342318, n=52) and older controlled optic-nerve trials (10741256, 11569188) — so 1A scores at the "controlled / multiple observational" band rather than a clean RCT; 1B held low ("some concerns": Russian trials lack clear randomization/blinding detail); total human N ~300-500 (1C ~8); stroke outcomes are direct (1D); 1E credits an extensive replicated preclinical program. Mechanism 74: well-mapped BDNF/NGF->TrkB neuroplasticity and transcriptome-wide RNA-Seq cascades (32580520, 34201112), a recent independent target identification via mu-opioid receptor with USP18 knockdown (40692165) lifting 2A toward the binding+functional+knockdown band, dose-response across in-vivo models (16362768), all confirmed in mammalian models. Plausibility 77: for stroke the mechanism->BDNF surrogate->Barthel clinical chain is supported end-to-end, fully coherent with neurotrophin biology, with melanocortin/ neurotrophic class analogy; minor deduction for multi-system (cognition, optic, ADHD) breadth. Global Coverage 62: historically a single Russian cluster (Kurchatov/Pirogov) but now genuinely replicated by independent groups in China (40692165), Indonesia, and Italy, ~30-60 studies across 4-6 countries, with Russian regulatory approval (4D=10). Community Experience 68: sustained 7+ year nootropic-community use across multiple venues, broadly consistent reported themes, only minor non-serious adverse reports. Effectiveness basis clinical (low confidence): Gusev stroke trial shows accelerated functional recovery / Barthel improvement and controlled optic-nerve trials show visual-function gains — moderate effect on hard patient-relevant outcomes, superior to placebo/rehab-alone but no head-to-head vs standard stroke care, and the entire efficacy base is Russian-origin with risk-of-bias concerns and no Western replication.
Semax has a complex, multi-target mechanism of action that distinguishes it from traditional nootropics. Unlike its parent ACTH molecule, Semax does not stimulate cortisol release, making it safe for long-term neurological use.
How It Works (Simplified)
Semax acts as a “brain fertilizer and protector” through several complementary pathways:
Rapidly increases BDNF and NGF expression within minutes of administration, supporting learning, memory, neuronal survival, and recovery from injury.
Activates dopamine and serotonin systems in striatum and frontal cortex, enhancing attention, motivation, and mood without depleting neurotransmitter stores.
Suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and chemokines following brain injury, protecting neurons from secondary damage.
Modulates hundreds of genes involved in neurotransmission, immune response, and cell survival, producing sustained benefits through transcriptional changes.
Important Limitations
- Most research originates from Russian institutions with limited Western independent replication
- Many primary studies published only in Russian, creating language barriers for verification
- Historical clinical trials may not meet current Western GLP/GCP standards
- Human pharmacokinetics and optimal dosing not fully characterized by Western standards
- No FDA or EMA regulatory pathway has been pursued
Reported positives
- Improved focus and mental clarity frequently reported
- Reduced brain fog and enhanced cognitive performance
- Mood improvement and reduced anxiety noted
- Nasal administration convenient and non-invasive
Reported negatives
- Effects short-lived requiring frequent redosing
- Hair loss reported by some long-term users
- Irritability and overstimulation at higher amounts
- Product quality varies between suppliers
“Popular nootropic in r/Nootropics and r/Peptides. Russian-approved drug with growing Western interest.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on preclinical and clinical data: Rapid BDNF/NGF upregulation begins within 30 minutes of intranasal administration. In stroke patients, early intervention shows greatest benefits. Dopamine and serotonin modulation observed.
PMID:16996037In stroke rehabilitation trials, BDNF levels increased significantly and functional recovery (Barthel scores) improved over 2-4 weeks. Anti-inflammatory effects reduce secondary brain damage. Clinical trials showed improved attention and cognitive function.
PMID:29798983Russian protocols typically use 10-14 day treatment courses. Long-term effects and optimal duration not characterized by Western standards. Some conditions may require repeated courses.
PMID:16362768Long-term maintenance protocols not well-established. Russian clinical practice suggests periodic treatment courses rather than continuous administration. Human pharmacokinetics not fully characterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Selank
SynergisticComplementary Russian regulatory peptides - Semax provides nootropic/neuroprotective effects via BDNF while Selank offers anxiolysis via GABA. Common clinical combination in Russia.
Epithalon
CompatibleBoth Russian bioregulator peptides with different CNS targets - Semax for acute neuroprotection via BDNF, epithalon for cellular longevity via telomeres.
BPC-157
CompatibleBoth have neuroprotective properties - Semax via BDNF/NGF upregulation, BPC-157 via multiple CNS repair mechanisms. May have complementary neuroprotective effects.
Thymosin-Alpha-1
CompatibleSemax has immunomodulatory effects alongside nootropic actions; Ta1 is primarily immunomodulatory. Different primary mechanisms with potential immune synergy.
TB-500
CompatibleBoth promote tissue repair - Semax in CNS via neurotrophins, TB-500 systemically via actin regulation. Different primary targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Semax
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.